Timing of Adjuvant and Neoadjuvant Therapy in Colorectal Cancers |
| |
| Authors: | Soley Bayraktar Ulas D. Bayraktar Caio M. Rocha-Lima |
| |
| Affiliation: | 1. Medical Department I, University Cancer Center, University Hospital Carl Gustav Carus, Dresden, Germany;2. Hospital de Sabadell, Corporació Sanitaria Parc Taulí-Institut Universitari, Sabadell, Spain;3. Department of Radiotherapy and Oncology, The Christie NHS Foundation Trust, Manchester;4. Department of Cancer Studies, University of Leicester, Leicester, UK;5. Department of Medical Oncology, Hospital Clinico Universitario e Instituto de Investigación, Santiago de Compostela, Spain;6. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea;7. Pyatigorsk Cancer Dispensary, Stavropol, Russia;8. Department I of Internal Medicine, Prosper Hospital, Recklinghausen, Germany;9. Department of Oncology and Hematology, Korea University Guro Hospital, Seoul, Republic of Korea;10. Department III of Internal Medicine, University Hospital, Mannheim, Germany;11. Department of Medical Oncology, Calvary Mater Hospital, Newcastle;12. Hunter Medical Research Institute and University of Newcastle, Callaghan, Australia;13. Department of Oncology, St James'' Hospital, Leeds, UK;14. Samara Regional Oncology Dispensary, Samara;15. Oncological Dispensary #2, Sochi, Russia;16. Cancer Services Division, Mount Vernon Cancer Centre, Middlesex;17. Department of Medical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, UK;18. Clinic of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany;19. School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia |
| |
| Abstract: | Surgery remains the only curative therapy for colorectal cancer (CRC); however, several studies have proved that adjuvant chemotherapy improves the curative rate. A growing body of evidence indicates that significant deviations from recommended treatment plans are frequent. Patients may experience delays in the administration of adjuvant chemotherapy that can reduce its survival benefit. To date, few studies have examined factors associated with the timing of adjuvant chemotherapy or have described the effects of delayed therapy on overall survival. In this review, we discuss the extent and predictors of delay in administration of adjuvant chemotherapy as well as the relationship between timing and outcomes in CRC. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
